ScienceMonday, October 26, 20261 min read

STAT+: Roche gets a lung cancer win with its KRAS drug divarasib

By Adam Feuerstein and Andrew Joseph · Via STAT Health · Published by Everything Blog

In short

Roche's drug divarasib has surpassed older KRAS inhibitors from Amgen and Bristol Myers Squibb, significantly improving overall survival rates in patients with KRAS G12C mutations. This is a significant win for Roche, highlighting the company's focus on targeted therapies for lung cancer.

Key points

Roche's drug divarasib has shown impressive results in treating advanced lung cancer.: Roche's drug divarasib has shown impressive results in treating advanced lung cancer.
The study's findings highlight Roche's advancements in lung cancer treatment.: The study's findings highlight Roche's advancements in lung cancer treatment.
Roche's focus on targeted therapies is a key area of its strategy.: Roche's focus on targeted therapies is a key area of its strategy.

Sources checked by our analysis pipeline: 1

You’re reading our ESMO in 30 Seconds newsletter. Sign up here to get updates from future major European cancer conferences in your inbox.

We’ve made it. Here’s our last newsletter from this year’s European Society for Medical Oncology meeting. But before we bust out of this convention center for the final time, a reminder that we’ll be recapping ESMO on Thursday at 10 a.m. Eastern. Register for the virtual event here, and thanks very much for reading.

Roche gets a lung cancer win

One of the more impressive data sets at this year’s ESMO came from a Roche study of its drug divarasib, which inhibits G12C KRAS mutations, in second-line advanced non-small cell lung cancer, where it outpaced older KRAS inhibitors from Amgen and Bristol Myers Squibb.

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Original source: www.statnews.com

AI Analysis

Tone

Positive

In short

Key Points

Roche's drug divarasib has shown impressive results in treating advanced lung cancer.: Roche's drug divarasib has shown impressive results in treating advanced lung cancer.
The study's findings highlight Roche's advancements in lung cancer treatment.: The study's findings highlight Roche's advancements in lung cancer treatment.
Roche's focus on targeted therapies is a key area of its strategy.: Roche's focus on targeted therapies is a key area of its strategy.

Topics

Science

Was this summary useful?

AI Analysis

Tone

Positive

In short

Key Points

Roche's drug divarasib has shown impressive results in treating advanced lung cancer.: Roche's drug divarasib has shown impressive results in treating advanced lung cancer.
The study's findings highlight Roche's advancements in lung cancer treatment.: The study's findings highlight Roche's advancements in lung cancer treatment.
Roche's focus on targeted therapies is a key area of its strategy.: Roche's focus on targeted therapies is a key area of its strategy.

Topics

Science

Was this summary useful?

OpenAI announces three big science discoveries and a new way to work with academics
OpenAI has made significant scientific advancements and introduced a new approach to academic collaboration, guiding external experts in the process. The company has released three mathematical results and a physics proof, including resolving the Kakeya conjecture and Stein's restriction conjecture in mathematics, and confirming the existence of interacting quantum field theories in physics. Additionally, OpenAI has introduced a method for sharing research findings with academics, where AI outputs are released on…
2 min read
Air quality remains in good-to-moderate range; NEA says low likelihood of haze today
Air quality in Singapore remains in the good-to-moderate range, with the National Environment Agency predicting low likelihood of smoke haze affecting the city-state on Tuesday. Prevailing winds and showers are expected over Singapore, with the 1-hour PM2.5 readings all within normal range and the 24-hour Pollutant Standards Index remaining in the good-to-moderate range. NEA advises to refer to the 24-hour PSI forecast and check the latest 1-hour PM2.5 readings for outdoor activities.
1 min read
Haze in Singapore: Normal PM2.5 and good to moderate 24-hour PSI readings islandwide
Despite a week of poor haze, Singapore's air quality improved significantly, with normal PM2.5 readings and good-to-moderate 24-hour PSI levels across the island. The National Environment Agency (NEA) noted that air quality was better after a week of poor haze, and showers and wet weather were expected to help keep smoke and hotspots down.
2 min read

STAT+: Roche gets a lung cancer win with its KRAS drug divarasib

In short

Key points

More in Science